FOCUS PHARMA
ActiveSummary
FOCUS PHARMA has been active since 2012 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€91,912) and a net result of -€20,562. Equity is shrinking by about 63% per year across the filed financial years. Its solvency ranks better than 5% of 9,770 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.7% (low).
Directors
Directors
2 directors, 1 in day-to-day management, last change in 2024
Board 2
Maria Lemmens
CurrentDirector · since 29-05-2024
Peter Van Ruyskensvelde
CurrentDirector · since 29-05-2024
Day-to-day management 1
Peter Van Ruyskensvelde
CurrentManaging director · since 29-05-2024
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
4 of this company's 5 Belgian Official Gazette deeds have not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.
Mandate history
2 people since 2024, 2 in office
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| Maria Lemmens |
|
| Peter Van Ruyskensvelde |
|
Owners and capital
Owners
No owners or capital events in the accounts and acts we read.